<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840772</url>
  </required_header>
  <id_info>
    <org_study_id>ISG-ERASING</org_study_id>
    <nct_id>NCT03840772</nct_id>
  </id_info>
  <brief_title>Eribulin in Advanced Solitary Fibrous Tumor</brief_title>
  <acronym>ERASING</acronym>
  <official_title>ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an Italian, non randomized, open label, multi center, investigator-initiated, Phase
      II, clinical study to explore the activity of eribulin in a population of patients with
      progressive, advanced (i.e. locally advanced or metastatic), molecularly proven SFT. Patients
      with a documented and centrally reviewed pathological diagnosis of locally advanced or
      metastatic SFT, and with an evidence of progression within the previous 6 months, may enter
      the study.

      Study treatments will be administered till progression or toxicity. The primary end-point of
      the study is overall response rate Secondary end-points are Progression Free Survival (PFS),
      Overall Survival (OS) clinical benefit rate, response rate as by Choi criteria, duration of
      response.

      Subjects already treated with one or two prior medical therapy regimens for the advanced
      phase, whatever agent used in first- or second-line, are eligible for inclusion in the study.
      Investigators will consider eligible for this study even patients naïve from chemotherapy,
      considering the limited activity of anthracycline in the disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Not controlled, single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RECIST 1.1 Overall response rate</measure>
    <time_frame>At week 6</time_frame>
    <description>Proportion of patients with tumor size reduction ⩾ to 30% measured with RECIST Criteria 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Choi Response Rate</measure>
    <time_frame>At week 6</time_frame>
    <description>Proportion of patients with tumor size reduction ⩾10% or a decrease in tumour attenuation⩾15% measured with Choi criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at 3 years</measure>
    <time_frame>At 3 years</time_frame>
    <description>Survival from the first eribulin dose to death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) at 3 years</measure>
    <time_frame>At 3 years</time_frame>
    <description>Survival without disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>At week 18</time_frame>
    <description>Proportion of patients with no disease progression after 18 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the treatment in term of adverse event</measure>
    <time_frame>Week 9, week 18, week 27, week 36</time_frame>
    <description>Safety in term of adverse event is evaluate from the first eribulin dose throughout the study according to CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Solitary Fibrous Tumor</condition>
  <arm_group>
    <arm_group_label>Eribulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eribulin will be administered at the dose of 1.23 mg/m², intravenously over 2-5 min on day 1 and day 8 of every 21 day cycle.
Study treatment will be administered until evidence of progression or unacceptable toxicity, patient's own willingness, non-compliance or according to clinical investigator's decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>Treatment with eribulin</description>
    <arm_group_label>Eribulin</arm_group_label>
    <other_name>Intervention under investigation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient or legal representative must be able to read and understand the informed
             consent form and must have been willing to give written informed consent and any
             locally required authorization before any study-specific procedures, including
             screening evaluations, sampling, and analyses

          2. Age ≥18 years

          3. Histological centrally and molecular confirmed diagnosis SFT

          4. Locally advanced disease and/or metastatic disease

          5. Measurable disease according RECIST 1.1

          6. Evidence of progression by RECIST 1.1 during the 6 months before study entry

          7. Patients must be treated with at least one prior medical anticancer treatment line for
             the advanced phase of disease (both cytotoxic chemotherapy or target treatment
             allowed) and with a maximum of 2 lines.

          8. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

          9. Adequate bone marrow function

         10. Adequate organ function

         11. Cardiac ejection fraction ≥50%

         12. Female patients of child-bearing potential must have negative pregnancy test within 7
             days before initiation each cycle of chemotherapy. Post-menopausal women must be
             amenorrhoeic for at least 12 months to be considered of non-childbearing potential.
             Male and female patients of reproductive potential must agree to employ an effective
             method of birth control throughout the study.

        Exclusion Criteria:

          1. Naïve patients

          2. More than 2 lines of anticancer treatment

          3. Previous treatment with any other anti-cancer investigational or not investigational
             agents within 21 days of first day of study drug dosing,

          4. Previous treatment with radiation therapy within 14 days of first day of study drug
             dosing, or patients who have not recovered from adverse events due to agents
             previously administered

          5. Previous radiotherapy to 25% of the bone marrow

          6. Major surgery within 21 days prior to study entry

          7. Other primary malignancy with &lt;5 years clinically assessed disease-free interval,
             except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged
             to entail a low risk of relapse

          8. Pregnancy or breast feeding

          9. Cardiovascular diseases resulting in a New York Heart Association Functional Status &gt;2
             . Medical history of a myocardial infarction &lt; 6 months prior to initiation of study
             treatment. Unstable angina or myocardial infarction within 6 months of enrolment,
             Serious and potentially life-threatening arrhythmia

         10. Subjects with a high probability of Long QT Syndrome or corrected QT interval
             prolongation of more than or equal to 501 msec , following correction of any
             electrolyte imbalance

         11. Medical history of arterial thrombotic or embolic events such as cerebrovascular
             accident (including transient ischemic attacks), or pulmonary embolism within 6 months
             prior to the initiation of study treatment

         12. Known history of human immunodeficiency virus infection

         13. Active or chronic hepatitis B or C requiring treatment with antiviral therapy

         14. Medical history of hemorrhage or a bleeding event ≥ Grade 3 according Common
             Terminology Criteria for Adverse Events (CTCAE) within 4 weeks prior to the initiation
             of study treatment

         15. Evidence of any other serious or unstable illness, or medical, psychological, or
             social condition, that could jeopardize the safety of the subject and/or his/her
             compliance with study procedures, or may interfere with the subject's participation in
             the study or evaluation of the study results

         16. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation of the study drugs

         17. Subjects who have not recovered from acute toxicities as a result of prior anti-cancer
             therapy to ≤ Grade 1 of CTCAE, except for peripheral neuropathy and alopecia.

         18. Pre-existing peripheral neuropathy &gt; CTCAE Grade 2.

         19. Expected non-compliance to medical regimens

         20. Subjects with known central nervous system metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Stacchiotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS INT di Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Stacchiotti, MD</last_name>
    <phone>0039022390</phone>
    <phone_ext>2803</phone_ext>
    <email>silvia.stacchiotti@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noemi Simone, MD</last_name>
    <phone>0039022390</phone>
    <phone_ext>2803</phone_ext>
    <email>noemi.simone@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Badalamenti, MD</last_name>
      <phone>0039091655</phone>
      <phone_ext>4513</phone_ext>
      <email>giuseppebadalamenti@unipa.it</email>
    </contact>
    <contact_backup>
      <last_name>Badalamenti</last_name>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Badalamenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Vincenzi, MD</last_name>
      <phone>+3902225411123</phone>
      <email>b.vincenzi@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Vincenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia IRCC Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS INT Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <phone>+39022390</phone>
      <phone_ext>2804</phone_ext>
      <email>silvia.stacchiotti@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Verbeke SL, Fletcher CD, Alberghini M, Daugaard S, Flanagan AM, Parratt T, Kroon HM, Hogendoorn PC, Bovée JV. A reappraisal of hemangiopericytoma of bone; analysis of cases reclassified as synovial sarcoma and solitary fibrous tumor of bone. Am J Surg Pathol. 2010 Jun;34(6):777-83. doi: 10.1097/PAS.0b013e3181dbedf1.</citation>
    <PMID>20421780</PMID>
  </reference>
  <reference>
    <citation>Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013 Feb;45(2):180-5. doi: 10.1038/ng.2509. Epub 2013 Jan 13.</citation>
    <PMID>23313952</PMID>
  </reference>
  <reference>
    <citation>Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, Stacchiotti S, Pierotti MA, Negri T, Pilotti S. Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Mod Pathol. 2015 Aug;28(8):1074-83. doi: 10.1038/modpathol.2015.70. Epub 2015 May 29.</citation>
    <PMID>26022454</PMID>
  </reference>
  <reference>
    <citation>Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery. 2008 Oct;63(4):720-6; author reply 726-7. doi: 10.1227/01.NEU.0000325494.69836.51.</citation>
    <PMID>18981882</PMID>
  </reference>
  <reference>
    <citation>Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. Cancer. 1998 May 15;82(10):1915-20.</citation>
    <PMID>9587125</PMID>
  </reference>
  <reference>
    <citation>Beadle GF, Hillcoat BL. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol. 1983 Mar;22(3):167-70.</citation>
    <PMID>6682161</PMID>
  </reference>
  <reference>
    <citation>Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, Casali PG. Response to chemotherapy of solitary fibrous tumour: a retrospective study. Eur J Cancer. 2013 Jul;49(10):2376-83. doi: 10.1016/j.ejca.2013.03.017. Epub 2013 Apr 6.</citation>
    <PMID>23566418</PMID>
  </reference>
  <reference>
    <citation>Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.</citation>
    <PMID>26874885</PMID>
  </reference>
  <reference>
    <citation>Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grünwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.</citation>
    <PMID>21937277</PMID>
  </reference>
  <reference>
    <citation>Kawai A, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y, Morioka H, Matsumine A, Saito K, Asami S, Isu K. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017 Feb 1;47(2):137-144. doi: 10.1093/jjco/hyw175.</citation>
    <PMID>28173193</PMID>
  </reference>
  <reference>
    <citation>Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002 Mar;38(4):543-9.</citation>
    <PMID>11872347</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solitary Fibrous Tumor</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>rare sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Fibrous Tissue</mesh_term>
    <mesh_term>Solitary Fibrous Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

